Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes

M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, D. M. Pollock

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Aims/hypothesis: Activation of endothelin receptor-A (ETA) increases glomerular permeability to albumin (Palb) and elevates pro-inflammatory markers in hyperglycaemic rats. Methods: Male Sprague-Dawley rats were given streptozotocin (n=32) or saline (sham; n=32). Half of the animals in each group received the ETA-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed. Glomeruli were isolated by sieving techniques and Palb determined from the change in glomerular volume induced by oncotic gradients of albumin. Glomerular nephrin levels were assessed by immunofluorescence, whereas urinary nephrin was measured by immunoassay. Results: At 3 and 6 weeks after streptozotocin injection, proteinuria was significantly increased compared with sham controls and significantly reduced by ABT-627 treatment. Palb was also increased at 3 and 6 weeks post-streptozotocin. ABT-627 had no effect on Palb or protein excretion in sham control rats. In glomeruli isolated from hyperglycaemic rats, incubation with BQ-123, a selective ET A antagonist, reduced Palb, whereas BQ-788, a selective endothelin receptor-B antagonist had no effect (n=6 rats per group, 5-8 glomeruli per rat). Glomerular and plasma content of soluble intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 were significantly increased 6 weeks after streptozotocin (ELISA). ABT-627 attenuated these increases. After 6 weeks of hyperglycaemia, glomerular nephrin content was decreased with a concurrent increase in urinary nephrin excretion. ABT-627 prevented glomerular nephrin loss in hyperglycaemic rats (n=5-8 rats per group; eight groups). Conclusions/interpretation: These observations support the hypothesis that endothelin-1, via the ETA receptor, directly increases Palb, possibly via nephrin loss, as well as early inflammation in the hyperglycaemic rat.

Original languageEnglish (US)
Pages (from-to)979-988
Number of pages10
JournalDiabetologia
Volume54
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Endothelin A Receptors
Streptozocin
Albumins
Inflammation
Permeability
Wounds and Injuries
Hyperglycemia
Chemokine CCL2
Endothelin-1
Intercellular Adhesion Molecule-1
Proteinuria
Immunoassay
Fluorescent Antibody Technique
Sprague Dawley Rats
atrasentan
nephrin
Enzyme-Linked Immunosorbent Assay
Injections

Keywords

  • Albuminuria
  • Diabetic nephropathy
  • Endothelin-1
  • Glomerular permeability
  • MCP-1
  • Nephrin
  • P
  • sICAM-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. / Saleh, M. A.; Boesen, E. I.; Pollock, J. S.; Savin, V. J.; Pollock, D. M.

In: Diabetologia, Vol. 54, No. 4, 01.04.2011, p. 979-988.

Research output: Contribution to journalArticle

Saleh, M. A. ; Boesen, E. I. ; Pollock, J. S. ; Savin, V. J. ; Pollock, D. M. / Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. In: Diabetologia. 2011 ; Vol. 54, No. 4. pp. 979-988.
@article{13e6a9b346ba497daebdbb416e17254f,
title = "Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes",
abstract = "Aims/hypothesis: Activation of endothelin receptor-A (ETA) increases glomerular permeability to albumin (Palb) and elevates pro-inflammatory markers in hyperglycaemic rats. Methods: Male Sprague-Dawley rats were given streptozotocin (n=32) or saline (sham; n=32). Half of the animals in each group received the ETA-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed. Glomeruli were isolated by sieving techniques and Palb determined from the change in glomerular volume induced by oncotic gradients of albumin. Glomerular nephrin levels were assessed by immunofluorescence, whereas urinary nephrin was measured by immunoassay. Results: At 3 and 6 weeks after streptozotocin injection, proteinuria was significantly increased compared with sham controls and significantly reduced by ABT-627 treatment. Palb was also increased at 3 and 6 weeks post-streptozotocin. ABT-627 had no effect on Palb or protein excretion in sham control rats. In glomeruli isolated from hyperglycaemic rats, incubation with BQ-123, a selective ET A antagonist, reduced Palb, whereas BQ-788, a selective endothelin receptor-B antagonist had no effect (n=6 rats per group, 5-8 glomeruli per rat). Glomerular and plasma content of soluble intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 were significantly increased 6 weeks after streptozotocin (ELISA). ABT-627 attenuated these increases. After 6 weeks of hyperglycaemia, glomerular nephrin content was decreased with a concurrent increase in urinary nephrin excretion. ABT-627 prevented glomerular nephrin loss in hyperglycaemic rats (n=5-8 rats per group; eight groups). Conclusions/interpretation: These observations support the hypothesis that endothelin-1, via the ETA receptor, directly increases Palb, possibly via nephrin loss, as well as early inflammation in the hyperglycaemic rat.",
keywords = "Albuminuria, Diabetic nephropathy, Endothelin-1, Glomerular permeability, MCP-1, Nephrin, P, sICAM-1",
author = "Saleh, {M. A.} and Boesen, {E. I.} and Pollock, {J. S.} and Savin, {V. J.} and Pollock, {D. M.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s00125-010-2021-4",
language = "English (US)",
volume = "54",
pages = "979--988",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes

AU - Saleh, M. A.

AU - Boesen, E. I.

AU - Pollock, J. S.

AU - Savin, V. J.

AU - Pollock, D. M.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Aims/hypothesis: Activation of endothelin receptor-A (ETA) increases glomerular permeability to albumin (Palb) and elevates pro-inflammatory markers in hyperglycaemic rats. Methods: Male Sprague-Dawley rats were given streptozotocin (n=32) or saline (sham; n=32). Half of the animals in each group received the ETA-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed. Glomeruli were isolated by sieving techniques and Palb determined from the change in glomerular volume induced by oncotic gradients of albumin. Glomerular nephrin levels were assessed by immunofluorescence, whereas urinary nephrin was measured by immunoassay. Results: At 3 and 6 weeks after streptozotocin injection, proteinuria was significantly increased compared with sham controls and significantly reduced by ABT-627 treatment. Palb was also increased at 3 and 6 weeks post-streptozotocin. ABT-627 had no effect on Palb or protein excretion in sham control rats. In glomeruli isolated from hyperglycaemic rats, incubation with BQ-123, a selective ET A antagonist, reduced Palb, whereas BQ-788, a selective endothelin receptor-B antagonist had no effect (n=6 rats per group, 5-8 glomeruli per rat). Glomerular and plasma content of soluble intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 were significantly increased 6 weeks after streptozotocin (ELISA). ABT-627 attenuated these increases. After 6 weeks of hyperglycaemia, glomerular nephrin content was decreased with a concurrent increase in urinary nephrin excretion. ABT-627 prevented glomerular nephrin loss in hyperglycaemic rats (n=5-8 rats per group; eight groups). Conclusions/interpretation: These observations support the hypothesis that endothelin-1, via the ETA receptor, directly increases Palb, possibly via nephrin loss, as well as early inflammation in the hyperglycaemic rat.

AB - Aims/hypothesis: Activation of endothelin receptor-A (ETA) increases glomerular permeability to albumin (Palb) and elevates pro-inflammatory markers in hyperglycaemic rats. Methods: Male Sprague-Dawley rats were given streptozotocin (n=32) or saline (sham; n=32). Half of the animals in each group received the ETA-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed. Glomeruli were isolated by sieving techniques and Palb determined from the change in glomerular volume induced by oncotic gradients of albumin. Glomerular nephrin levels were assessed by immunofluorescence, whereas urinary nephrin was measured by immunoassay. Results: At 3 and 6 weeks after streptozotocin injection, proteinuria was significantly increased compared with sham controls and significantly reduced by ABT-627 treatment. Palb was also increased at 3 and 6 weeks post-streptozotocin. ABT-627 had no effect on Palb or protein excretion in sham control rats. In glomeruli isolated from hyperglycaemic rats, incubation with BQ-123, a selective ET A antagonist, reduced Palb, whereas BQ-788, a selective endothelin receptor-B antagonist had no effect (n=6 rats per group, 5-8 glomeruli per rat). Glomerular and plasma content of soluble intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 were significantly increased 6 weeks after streptozotocin (ELISA). ABT-627 attenuated these increases. After 6 weeks of hyperglycaemia, glomerular nephrin content was decreased with a concurrent increase in urinary nephrin excretion. ABT-627 prevented glomerular nephrin loss in hyperglycaemic rats (n=5-8 rats per group; eight groups). Conclusions/interpretation: These observations support the hypothesis that endothelin-1, via the ETA receptor, directly increases Palb, possibly via nephrin loss, as well as early inflammation in the hyperglycaemic rat.

KW - Albuminuria

KW - Diabetic nephropathy

KW - Endothelin-1

KW - Glomerular permeability

KW - MCP-1

KW - Nephrin

KW - P

KW - sICAM-1

UR - http://www.scopus.com/inward/record.url?scp=79953828524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953828524&partnerID=8YFLogxK

U2 - 10.1007/s00125-010-2021-4

DO - 10.1007/s00125-010-2021-4

M3 - Article

C2 - 21191784

AN - SCOPUS:79953828524

VL - 54

SP - 979

EP - 988

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 4

ER -